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Objectives. The purpose of this study was to compare the
outcome of primary percutaneous transluminal coronary angio-
plasty for acute myocardial infarction (MI) when performed with
or without the platelet glycoprotein IIb/IIIa antibody, abciximab.
Background. Abciximab improves the outcome of angioplasty
but the effect of abciximab in primary angioplasty has not been
investigated.
Methods. Data were collected from a computerized database.
Follow-up was by telephone or review of outpatient or hospital
readmission records.
Results. A total of 182 consecutive patients were included; 103
received abciximab and 79 did not. The procedural success rate
was 95% in the two groups. At 30-day follow-up, the composite
event rate of unstable angina, reinfarction, target vessel revascu-
larization and death from all causes was 13.5% in the group of
patients who did not receive abciximab, 4% (p < 0.05) in the
abciximab group and 2.4% (p < 0.05) in the subgroup of patients
(n 5 87) who completed the 12-h abciximab infusion. At the end
of follow-up (mean 7 6 4 months), the composite event rate was
32.4%, 17% (p < 0.05) and 13.1% (p < 0.01) in these three
categories respectively. Abciximab bolus followed by a 12-h infu-
sion was an independent predictor of event-free survival, in a Cox
proportional hazards model (relative risk 0.49; 95% confidence
interval 0.24 to 0.99; p < 0.05).
Conclusions. Abciximab given at the time of primary angio-
plasty may improve the short- and medium-term outcome of
patients with acute MI, especially when a 12-h infusion is com-
pleted.
(J Am Coll Cardiol 1998;32:1996–2002)
©1998 by the American College of Cardiology
Platelet aggregation and activation play a key role in the
thrombotic process resulting from plaque rupture in acute
myocardial infarction (MI) (1) and during percutaneous trans-
luminal coronary angioplasty (PTCA) (2,3). Trials with aspirin
have confirmed a significant reduction in morbidity and mor-
tality with antiplatelet therapy in these conditions (4–6). More
potent platelet antagonists have recently been developed, such
as the chimeric monoclonal antibody c7E3 or abciximab,
directed against the platelet membrane glycoprotein (GP)
IIb/IIIa receptor (7). Abciximab markedly inhibits platelet
aggregation in a dose-dependent manner (8) and significantly
reduces ischemic events in patients undergoing percutaneous
coronary revascularization (9,10), particularly those with un-
stable angina or recent MI (9,11).
Primary angioplasty performed as soon as possible after the
onset of symptoms is an efficient modality for the treatment of
acute MI (12). However, despite an initial high success rate, it
is still limited by recurrent ischemia that can lead to repeat
catheterization before or soon after hospital discharge (12–14).
Restenosis is also higher than after elective angioplasty
(15,16). Thus patients with acute MI undergoing primary
angioplasty represent a high risk group that may particularly
benefit from c7E3 therapy given at the time of the procedure.
This novel use of abciximab has not yet been fully investigated.
The purpose of this study was to assess if the addition of c7E3
to primary angioplasty for acute MI improves the short- and
medium-term outcomes of these patients.
Methods
Study population. The cardiac catheterization laboratory
database at Hartford Hospital was reviewed from April 1996 to
July 1997 to identify patients who underwent primary angio-
plasty for acute MI. For the purpose of the study, MI was
defined as chest pain consistent with myocardial ischemia, with
at least 1-mm ST segment elevation in two or more contiguous
electrocardiographic (ECG) leads, or as ongoing chest pain
refractory to medical therapy and associated with ST segment
depression or left bundle branch block. Patients with postin-
farction angina, failed thrombolytic therapy and angioplasty of
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a bypass graft were excluded. A total of 182 consecutive
patients met these criteria; they were all included in the study.
Procedural characteristics. All patients were initially
treated with aspirin and intravenous heparin, given as a
5,000-U bolus followed by a continuous infusion, and were
immediately taken to the cardiac catheterization laboratory.
Patients also received nitrates unless they were hypotensive or
in cardiogenic shock. The heparin dose was not adjusted to
body weight, and an additional 5,000 to 10,000 U were given to
all patients during angioplasty to achieve an activated clotting
time above 300 s. Angioplasty was performed in the standard
fashion. Intracoronary stenting with Palmaz-Schatz (Johnson
and Johnson) stent was performed in 48% of the cases (51% of
abciximab patients and 43% of control subjects; p 5 0.32).
Stent implantation was decided solely by the operator and was
either planned (primary elective stenting), or placed for sub-
optimal results or as a bailout for complications. All patients
who had a stent received ticlopidine, which was started as a
single dose of 500 mg immediately after the procedure and
continued at 250 mg twice a day (in addition to aspirin) for a
period of 4 weeks. Use of abciximab was left to the discretion
of the operator. Abciximab was given as a bolus of 0.25 mg/kg
body weight, followed by a 12-h infusion at a rate of 10 mg/min.
All sheaths were removed within the next 24 h, once the
activated coagulation time dropped below 180 s, or earlier if
local complications occurred.
Data collection. Clinical data were collected while patients
were hospitalized, and entered into the database. All data were
verified by retrospective review of patient records. Postdis-
charge follow-up was obtained via telephone calls or by review
of outpatient clinic charts. If a clinical event was reported, it
was confirmed by review of hospitalization records. Follow-up
was performed without knowledge of the procedural charac-
teristics of the primary angioplasty (i.e., stent use, abciximab
administration). Recurrent unstable angina after hospital dis-
charge was defined as readmission with typical chest pain
associated with either ischemic ECG findings, new myocardial
perfusion abnormalities on nuclear imaging in cases where a
baseline perfusion study was available or refractory chest pain
requiring repeat coronary revascularization. Reinfarction be-
fore hospital discharge was defined as an increase in the
activity of creatine kinase or its MB fraction of at least 50%
from the previous trough, and remaining at least twice the
upper limits of normal. Reinfarction occurring after discharge
was defined as recurrence of typical chest pain associated with
at least a twofold elevation in cardiac enzymes, or with new
abnormal Q waves in two or more contiguous leads.
All coronary angiograms were reviewed by an interven-
tional cardiologist without knowledge of abciximab adminis-
tration or patient outcome. Mean diameter stenosis (visual
estimation), Thrombolysis in Myocardial Infarction trial
(TIMI) coronary blood flow grade (17) and thrombus score
were determined before and after the procedure. The follow-
ing thrombus score was used: 0 5 no angiographically visible
thrombus, 1 5 possible thrombus, 2 5 definite thrombus
#3 mm in diameter and 3 5 definite thrombus .3 mm in
diameter.
Study end points. The primary end point of the study was
a prespecified composite of any of the following during the
total follow-up period: death from any cause, acute coronary
syndrome (unstable angina or myocardial infarction) and
target vessel revascularization. The later included patients who
underwent emergent or elective repeat percutaneous revascu-
larization or bypass surgery of the target vessel because of
recurrent ischemia, but did not include patients with multives-
sel disease who had successful primary angioplasty and later
underwent scheduled elective bypass surgery during which the
target vessel was revascularized. A secondary end point was the
same composite event rate at 30 days from primary angio-
plasty.
Statistical analysis. All continuous variables were ex-
pressed as mean value 6 SD, and were compared with a
two-tailed Student t test. Categoric data were presented as
absolute value and percent and were compared with a Fischer
exact or a chi-square test. The primary end point of the trial
was analyzed by evaluating the time to the first occurrence of
any one of the components of the composite end point that
occurred during the follow-up period. The results in the
treatment groups are displayed as Kaplan–Meier event-free
survival curves, which were compared by the log-rank method.
Multivariate correlates of survival were analyzed with Cox
model analysis. A p value ,0.05 was considered statistically
significant. Statistical tests were performed using commercially
available software (SPSS 8.0, Chicago, IL).
Results
Clinical and procedural characteristics. Of the 182 con-
secutive patients included in this analysis, 103 patients received
abciximab and 79 did not (“no abciximab” group). In the
abciximab group, the bolus of c7E3 was administered 5 to
10 min before crossing the lesion with the angioplasty guide
wire in 79% of cases, and later during or immediately after the
procedure in the remaining cases. Abciximab infusion was
continued for 12 h in 87 patients (84%) but discontinued
earlier in the remaining 16 patients because of need for early
bypass surgery (three patients), and bleeding complications (13
patients). Mean activated clotting times were 343 6 109 s and
376 6 113 s (p , 0.05) in the abciximab and “no abciximab”
groups respectively. Heparin was continued after the proce-
dure in 29 (28%) abciximab patients (mean duration 26 6
Abbreviations and Acronyms
ECG 5 electrocardiographic
EPIC 5 Evaluation of c7E3 for the Prevention of Ischemic
Complications
GP 5 glycoprotein
MI 5 myocardial infarction
TIMI 5 Thrombolysis in Myocardial Infarction
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19 h) compared to 67 (85%) of patients who did not receive
c7E3 (mean duration 24 6 22 h).
Clinical characteristics (Table 1) were similar between the
two groups, except that diabetes mellitus and hypertension
were less prevalent in abciximab patients (9% and 38% vs. 24%
and 57% respectively; p , 0.05 for both).
The total procedural acute success rate (TIMI III flow with
#50% residual stenosis) was 95%. The procedural character-
istics (Table 2) were similar between the two groups, except
that abciximab patients had higher thrombus scores (1.46 6
0.88 vs. 1.05 6 0.6; p , 0.001) and lower activated clotting
times measured before balloon dilatation (343 6 109 vs. 376 6
113 s; p , 0.05). After the procedure, 97% of patients had
elevation in their cardiac enzymes more than twice the upper
normal limit, confirming the diagnosis of acute myocardial
infarction.
Thirty-day outcome. A mean follow-up of 7 6 4 months
was available on 174 patients (97% of the abciximab and 94%
of the “no abciximab” patients; p 5 NS). Follow-up was
obtained by telephone calls in 157 patients (90%) and by
review of outpatient clinical charts in 17 patients (10%). All
reported clinical events were confirmed by review of hospital-
ization records.
At 30 days, only four events (4%) occurred in the abciximab
group compared to 10 (13.5%) in the “no abciximab” group
(p , 0.05) (Table 3). This reduction was more important in
patients who completed the 12 h infusion, as only two patients
of the 84 on whom follow-up was available reached the
composite end point (2.4%; p , 0.05).
Because more diabetics were present in the “no abciximab”
group, and previous studies have associated diabetes mellitus
with more complications following angioplasty (18,19), we
measured the outcome in the two groups after exclusion of
diabetic patients. The benefit of abciximab was maintained
with a composite event rate of 3.3% at 30 days, in all patients
who were treated with c7E3, compared to 15.8% in patients
who did not receive abciximab (p , 0.05; Table 4).
Medium-term outcome. Follow-up duration was shorter
for abciximab patients (6 6 3.6 vs. 8.3 6 4 months; p , 0.001),
reflecting the later introduction of abciximab into practice.
Most of the events, however, occurred during the 2nd month
after the index procedure; the average time to event was 2.4 6
2.8 months in the abciximab group compared to 2.0 6 1.8
months in patients who were not treated with abciximab (p 5




(n 5 79) p
Age (yr) 60 6 13 61 6 11 NS
Male gender (%) 72 (70) 48 (61) NS
Risk factors
Diabetes (%) 9 (9) 19 (24) , 0.01
Hypertension (%) 39 (38) 45 (57) , 0.05
Tobacco (%) 47 (46) 40 (51) NS
Hypercholesterolemia (%) 44 (43) 30 (38) NS
Family history (%) 44 (43) 31 (39) NS
Previous infarction (%) 11 (11) 13 (16) NS
Prior angioplasty (%) 9 (9) 8 (10) NS
Prior bypass surgery (%) 0 (0) 4 (5) NS
Anterior wall infarction (%) 38 (37) 29 (37) NS
ST elevation on electrocardiogram
(%)
94 (91) 69 (87) NS
Cardiogenic shock (%) 11 (11) 12 (15) NS
Ejection fraction (mean 6 SD) 45 6 11% 44 6 11% NS
Coronary artery disease
1 vessel (%) 44 (43) 31 (39) NS
3 vessels (%) 30 (29) 21 (27) NS
Symptoms duration* (mean 6 SD) 3.7 6 4.6 4.2 6 4.8 NS
*Duration of chest pain prior to intervention.




(n 5 79) p
Diameter stenosis before procedure
(mean 6 SD)
98 6 5% 97 6 5% NS
TIMI 0-1 grade flow before procedure
(%)
77 (75) 60 (76) NS
Thrombus score before procedure
(mean 6 SD)
1.46 6 0.88 1.05 6 0.6 , 0.001
Diameter stenosis after procedure
(mean 6 SD)
14 6 17% 15 6 15% NS
TIMI 3 grade flow after procedure
(%)
98 (95) 77 (97) NS
Thrombus score after procedure
(mean 6 SD)
0.21 6 0.54 0.16 6 0.52 NS
Activated clotting time* (s) 343 6 109 376 6 113 0.048
Stent placement (%) 53 (51) 34 (43) NS
Left anterior descending artery
angioplasty (%)
39 (38) 26 (33) NS
Intraaortic balloon pump (%) 10 (10) 9 (11) NS
No reflow (%) 7 (7) 4 (5) NS
*Before first balloon inflation. TIMI 5 Thrombolysis in Myocardial Infarc-
tion.
Table 3. Events at 30 Days
All Abciximab
Patients (n 5 100)
12-h Infusion
Patients (n 5 84)
No Abciximab
Patients (n 5 74)
UA or MI (%) 1 (1)* 1 (1.2) 6 (8.1)
TVR (%) 2 (2) 2 (2.4) 5 (6.7)
Death (%) 3 (3) 1 (1.2) 4 (5.4)
Total events (%) 4 (4)* 2 (2.4)* 10 (13.5)
*p , 0.05 compared to no abciximab. MI 5 myocardial infarction; TVR 5
target vessel revascularization; UA 5 unstable angina.
Table 4. Composite Event Rates at 30 Days and During the Total












30 days (%) 3 (3.3)* 2 (2.6)* 9 (15.8)
Total follow-up (%) 12 (13.2)* 8 (10.2)† 18 (31.6)
*p , 0.05. †p , 0.01.
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NS). During that period, a total of 17 (17%) abciximab patients
reached the composite end point compared to 24 (32.4%) of
patients in the “no abciximab” group (p , 0.05). This reduc-
tion was seen in all three components of the composite end
point, but was statistically significant only in the recurrent
unstable angina or reinfarction category (7% vs. 21.6%; p ,
0.01) (Table 5). The composite event rate was lower in the
subgroup of patients who completed the 12-h infusion (13.1%)
(p , 0.01). Kaplan–Meier event-free survival curves during the
total follow-up period are represented in Figure 1. Abciximab
therapy resulted in better event-free survival, especially when a
12-h infusion was completed. Similar to the 30-day outcome,
the protection conferred by GP IIb/IIIa antagonists persisted
when diabetic subjects were excluded, with composite event
rates of 13.2% in patients treated with abciximab compared to
31.6% (p , 0.05) in those who were not treated with abciximab
(Table 4).
Because as many as 48% of our patients had at least one
coronary stent implanted during angioplasty, we performed a
subanalysis to assess the efficacy of the recommended abcix-
imab regime (bolus 1 12-h infusion) in primary angioplasty
and stenting. Figure 2 shows the Kaplan–Meier event-free
survival curves for the four subgroups (angioplasty, angio-
plasty 1 stent, angioplasty 1 abciximab, angioplasty 1 stent 1
abciximab) for the total follow-up duration. Stent implantation
alone did not provide additional benefit compared to the
subgroup of patients who were not stented, but the combina-
tion of stenting and abciximab bolus plus 12-h infusion resulted
in the best outcome.
Predictors of the medium-term outcome. In a univariate
analysis, the predictors of the medium-term outcome were:
gender, completion of 12-h abciximab infusion, number of
vessels with coronary artery disease, use of abciximab, diabetes
mellitus and cardiogenic shock. In a multivariate analysis using
a Cox regression model that included all these variables,
gender, single vessel coronary disease and completion of a 12-h
abciximab infusion were the only independent predictors of
event-free survival (Table 6). Abciximab use (with or without a
12-h infusion) was however, not a significant predictor of
outcome in this multivariate analysis.
Bleeding complications. Major bleeding requiring blood
transfusion occurred in 13 abciximab-treated patients (12.6%)
and 5 (6.3%) of the nontreated patients (p 5 0.24). Most
bleeding complications occurred at the femoral access site, as
groin or retroperitoneal hematomas in 12 of the 18 cases
(67%). There was no intracranial hemorrhage, and none of the
Table 5. Events During the Total Follow-up Period
All Abciximab
Patients (n 5 100)
12-h Infusion
Patients (n 5 84)
No Abciximab
Patients (n 5 74)
UA or MI (%) 7 (7)* 5 (5.9)* 16 (21.6)
TVR (%) 8 (8) 8 (9.5) 13 (17.5)
Death (%) 5 (5) 1 (1.2)† 9 (12.1)
All events (%) 17 (17)† 11 (13.1)* 24 (32.4)
*p # 0.01 and †p , 0.05 compared to no abciximab. Abbreviations as in
Table 3.
Figure 1. Event-free survival during the total follow-up period. The y
axis represents the percentage of patients without an event at the time
of follow-up (x axis). The number and percentage of patients assessed
at each time interval are shown below the x axis. *p , 0.01; **p , 0.05.
Figure 2. Event-free survival in the four subgroups of treatment. The
y axis represents the percentage of patients without an event at the
time of follow-up (x axis). The number and percentage of patients
assessed at each time interval are shown below the x axis. *p , 0.01;
**p 5 0.07 compared to no stent, no infusion.







Male gender 0.33 0.18 to 0.62 , 0.01
12-h abciximab infusion 0.36 0.18 to 0.73 , 0.01
Single vessel disease 0.39 0.18 to 0.82 , 0.05
Abciximab use 0.52 0.28 to 0.97 , 0.05
Diabetes mellitus 2.05 1.02 to 4.1 , 0.05
Cardiogenic shock 2.2 1.06 to 4.68 , 0.05
Multivariate predictors
Male gender 0.40 0.21 to 0.76 , 0.01
Single vessel disease 0.46 0.22 to 0.98 , 0.05
12-h abciximab infusion 0.49 0.24 to 0.99 , 0.05
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deaths was directly related to bleeding. Six patients also
received blood transfusion after coronary bypass surgery (four
patients who received abciximab and two patients who did not
receive it) and after abdominal surgery (one patient who was
not treated with abciximab and whose course was complicated
with ischemic bowel). An additional 10 patients (five in each
group) were transfused for a hematocrit less than 28% without
a clinical source of blood loss. Thus, the total transfusion rate
was 21.3% in patients treated with abciximab and 16.4% in
those who were not (p 5 NS).
Discussion
Despite an initial high success rate, primary angioplasty for
acute myocardial infarction is associated with significant short-
and long-term ischemic complications (12–16). In this series,
the composite rate of death from all causes, recurrent unstable
coronary syndromes and target vessel revascularization was
13.5% at 30 days, and 32.4% after a mean follow-up of 8.3
months, in the angioplasty group. Use of abciximab reduced
the composite event rate to 4% at 30 days and to 17% after a
mean follow-up of 6 months (70% and 47% reductions respec-
tively). This benefit was more significant when the 12-h infu-
sion was completed, with composite event rates of 2.4% and
13.1% during the short- and medium-term follow-up.
The present study is to our knowledge one of the first to
directly address the use of abciximab in primary angioplasty for
acute myocardial infarction. The results observed were similar
to those recently reported in prospective trials using abciximab
in high risk angioplasty. In the EPIC (Evaluation of c7E3 for
the Prevention of Ischemic Complications) trial, abciximab
bolus and infusion reduced the composite event rate by 35% at
30 days (9). The benefit persisted for 3 years in high risk
patients (20). In EPIC, only 42 patients had primary angio-
plasty within 12 h of an acute myocardial infarction. Of those,
15 received abciximab bolus and infusion. Despite their limited
number, a significant improvement in outcome was demonstra-
ble at 6 months follow-up (21). Other than the EPIC post hoc
subanalysis (which combined primary and rescue angioplasty
together), trials on GP IIb/IIIa receptor inhibitors in primary
angioplasty for acute myocardial infarction are still lacking.
Rationale for abciximab use in primary angioplasty. Mul-
tiple mechanisms may account for the efficacy of c7E3 in acute
myocardial infarction. Most of the periprocedural complica-
tions of angioplasty are related to the thrombotic milieu of the
unstable plaque. Several studies have demonstrated higher
complication rates following intervention in thrombus-
containing lesions (22) or in syndromes associated with intra-
coronary thrombosis (23). Platelet inhibition with aspirin in
acute myocardial infarction and during angioplasty has long
been established as an effective therapy, with reduction in
acute thrombotic complications and in late clinical events
(4–6). Abciximab is a more potent antiplatelet agent and may
work in a similar but more effective fashion, converting the
fissured or ruptured plaque and the endothelial surface from a
platelet-reactive to a platelet-nonreactive surface. This potent
antithrombotic action allows dissolution of preexisting clot and
improvement of coronary blood flow, when used before (24) or
after balloon inflation (rescue abciximab) (25) and may pre-
vent distal embolization and the no-reflow phenomenon seen
in primary angioplasty (26).
A 12-h infusion following abciximab bolus appears to be
very important to obtain complete platelet inhibition and to
achieve a significant antithrombotic effect. Similar to the EPIC
trial (9), the best results in our series were obtained in patients
who completed the 12-h infusion after an initial abciximab
bolus. In the CAPTURE (c7E3 Fab Antiplatelet Therapy in
Unstable Refractory Angina) trial, abciximab started 18–24 h
before PTCA and continued for 1 h after the procedure,
reduced myocardial infarction and death rates at 30 days,
without benefit at 6 months (27). This may be related to
interruption of therapy 1 h after angioplasty.
c7E3 and stents. Our results also suggest that combination
of GP IIb/IIIa receptor blockers and stenting may be synergis-
tic. Platelets are deposed heavily on the stent surface after its
deployment, and their degree of activation is an independent
predictor of acute stent thrombosis (28). In animal studies,
acute stent thrombosis was less frequent in polymer-coated
stents eluting platelet GP IIb/IIIa receptor antibody (29) and
after systemic pretreatment with c7E3 (30). Human studies
using these agents are underway, but recent trials showing the
efficacy of ticlopidine have provided indirect evidence that
more powerful antiplatelet therapy may be useful (31).
Whereas the primary benefit of stenting is to prevent abrupt
closure and restenosis, GP IIb/IIIa antagonists reduce subse-
quent unstable coronary syndromes, providing further im-
provement in the outcome of patients with acute myocardial
infarction.
Bleeding risk. The transfusion rate in this series was higher
than that previously reported for high risk angioplasty (9,12).
The heparin dose was not adjusted to body weight, resulting in
very high activated clotting times. Furthermore, heparin was
continued after the procedure in 28% of patients who received
abciximab and 85% of those who did not. These reasons may
account for the high transfusion rate observed. Recent studies
have emphasized that fewer bleeding complications occur with
a less aggressive heparinization protocol aiming for activated
clotting times in the 200-s range, and with early sheath removal
after the procedure (10,27). The use of percutaneous puncture
closure devices has also been shown to be a superior tool to
manual pressure technique to achieve femoral hemostasis (32)
and may be particularly useful after abciximab administration.
The low threshold for blood transfusion followed in our
coronary care unit to maintain oxygen delivery for acute
myocardial infarction patients might also have contributed to
the high transfusion rate. A recent study found that 64% of
blood transfusion after percutaneous coronary interventions
were inappropriate and did not adhere to the American
College of Physicians guidelines for transfusion (33).
Study limitations and clinical implications. This study is
limited by its observational nature and by the fact that abcix-
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imab was given in a nonrandomized fashion. Diabetes mellitus
and hypertension were more prevalent in the group of patients
who did not receive abciximab. Although abciximab benefit
persisted when diabetics were excluded from the analysis and
the regime combining a bolus plus a 12-h infusion was indepen-
dently associated with risk reduction in the regression model, a
selection bias favoring abciximab patients cannot be completely
excluded. On the other hand, despite abciximab patients having
higher thrombus scores and in many instances receiving abcix-
imab as “rescue” after one or more balloon inflations, abciximab
therapy remained associated with a better outcome.
The mean follow-up duration was also slightly longer in the
“no abciximab” group (8.4 vs. 6.1 months). This, however,
would not account for the improved clinical results at 30 days,
and is unlikely to affect the medium-term follow-up, because
the majority of events occurred early during the 2nd month.
This is confirmed by Kaplan–Meier event-free survival curves,
where the reduction in events started early and persisted
during the following months.
Stent implantation was also not randomized. Because of the
observational nature of this study, we were not always able to
define retrospectively the exact indication for stenting. It is
likely, however, that operators would be unwilling to leave a
suboptimal angioplasty result if stenting was technically feasi-
ble. It is probable that many patients had stents for less than
optimal angioplasty results as well as bailout for complications.
On the other hand, patients who did not receive a stent might
have had “stent-like” balloon angioplasty results. The fact that
stents did not improve outcome compared to balloon angio-
plasty may reflect a bias in placing stents after suboptimal or
failed angioplasty attempts. Abciximab bolus and perfusion
however, improved the outcome in the two groups of patients
who did and did not receive a stent.
In conclusion, patients with acute myocardial infarction
undergoing primary percutaneous revascularization with bal-
loon angioplasty and/or stents represent a high risk group
where platelet glycoprotein IIb/IIIa therapy may be particu-
larly beneficial. This study suggests that abciximab may im-
prove their short- and medium-term outcomes. The advantage
of primary angioplasty over thrombolytic therapy (34) may
thus be further improved or maintained over a longer duration
when abciximab is used at the time of angioplasty.
Addendum. The Randomized, Placebo-controlled Trial of
Platelet Glycoprotein IIb/IIIa Blockade With Primary Angio-
plasty for Acute Myocardial Infarction (RAPPORT) was pub-
lished after submission of this manuscript (Circulation 1998;
98:734–41).
We thank Jeff Mather, MS, for his excellent statistical assistance, and Roger
Mennett for his technical support.
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